Search Result

Results for "

antiplatelet aggregation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adrenergic Receptor (1) Apoptosis (2) Cytochrome P450 (3) HSP (1) Integrin (1) JAK (1) NADPH Oxidase (1) NF-κB (2) NO Synthase (1) P2Y Receptor (13) PI3K (1) Platelet-activating Factor Receptor (PAFR) (2) Prostaglandin Receptor (2) Protease Activated Receptor (PAR) (4) Src (1) Syk (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (29) Endocrinology (1) Infection (3) Inflammation/Immunology (8) Neurological Disease (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146498

Antiplatelet agent 1	P2Y Receptor	Cardiovascular Disease Cancer
Antiplatelet agent 1 (compound 7q) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 1 can be used for researching platelet aggregation .

HY-146499

Antiplatelet agent 2	P2Y Receptor	Cardiovascular Disease Cancer
Antiplatelet agent 2 (compound 7p) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 2 can be used for researching platelet aggregation .

HY-N7991

Rubiayannone A

Others Cardiovascular Disease

Rubiayannone A is an anthraquinone glycoside with an antiplatelet aggregation activity .

Rubiayannone A	Others	Cardiovascular Disease
Rubiayannone A is an anthraquinone glycoside with an antiplatelet aggregation activity .

HY-N3048

Piperlotine D	Others	Cardiovascular Disease
Piperlotine D is an antiplatelet aggregation agent. Piperlotine D can be extracted from Piper lolot with antiplatelet aggregation activity. Piperlotine D inhibits arachidonic acid-induced platelet aggregation with an IC₅₀ of 43.4 μg/mL .

HY-125123

Euchrestaflavanone A	Others	Cardiovascular Disease
Euchrestaflavanone A is a flavonoid found in the root bark of Cudrania tricuspidate. Euchrestaflavanone A inhibits platelet aggregation and has some antiplatelet and antithrombotic properties, making it a potential compound for thromboprophylaxis .

HY-111755

Oral antiplatelet agent 1	P2Y Receptor	Cardiovascular Disease
Oral antiplatelet agent 1 is a potent P2Y₁₂ receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC₅₀ value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .

HY-15799

AZD1283	P2Y Receptor	Cardiovascular Disease
AZD1283 is a potent P2Y₁₂ receptor antagonist with a binding IC₅₀ of 11 nM and a GTPγS IC₅₀ of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders .

HY-N4228

6-Methoxydihydroavicine	Platelet-activating Factor Receptor (PAFR)	Cancer
6-Methoxydihydroavicine is an alkaloid isolated from Zanthoxylum integrifoliolum. 6-Methoxydihydroavicine has *antiplatelet* activities and inhibits AA-, collagen- and PAF-induced platelet aggregation in vitro .

HY-N2081

Skimmianine 1 Publications Verification	Others	Inflammation/Immunology Cancer
Skimmianine is a furoquinoline alkaloid present mainly in the Rutaceae family, with antispastic, anti-inflammatory activities and antiplatelet aggregation effect. Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity .

HY-B0428A

Ozagrel sodium 1 Publications Verification OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC₅₀ of 53.12 μM .

HY-B0428

Ozagrel 1 Publications Verification OKY-046	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC₅₀ of 53.12 μM .

HY-N11920

Kadsurenin B	Platelet-activating Factor Receptor (PAFR)	Infection Neurological Disease Inflammation/Immunology
Kadsurenin B is a PAF (platelet-activating factor) antagonist with neuroprotective activity. Kadsurenin B has a wide range of pharmacological research potential, such as antibacterial, anti-inflammatory, neuroprotective, antioxidant, antiplatelet aggregation, cytotoxic, antiparasitic, etc .

HY-19638A

Cangrelor tetrasodium 1 Publications Verification AR-C69931MX tetrasodium	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .

HY-17459

Clopidogrel hydrogen sulfate Maximum Cited Publications 17 Publications Verification (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate	Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel hydrogen sulfate is an *antiplatelet* agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-N0293

Paeoniflorin 15+ Cited Publications Peoniflorin	HSP	Infection Neurological Disease Cancer
Paeoniflorin is a heat shock protein-inducing compound and commonly exists in the plants of Paeoniaceae family, with various biological activities, including anticancer activity, anti-inflammatory activity, enhancing cognition and attenuating learning impairment, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, and reducing blood viscosity .

HY-33351

Eugenin

Eugenin is a chromone isolated from Peucedanum japonicum, with potent antiplatelet aggregation activity .
HY-N3051

Piperlotine A

Others Cardiovascular Disease

Piperlotine A is an alkaloid isolated from Piper lolot, with potent antiplatelet aggregation activity .

Eugenin
Eugenin is a chromone isolated from Peucedanum japonicum, with potent antiplatelet aggregation activity .

Piperlotine A	Others	Cardiovascular Disease
Piperlotine A is an alkaloid isolated from Piper lolot, with potent antiplatelet aggregation activity .

HY-N3047

Piperolactam C O-Methylpiperolactam B; Piperolactam B methyl ether	Others	Cardiovascular Disease
Piperolactam C (O-Methylpiperolactam B) is a natural alkaloid with anti-platelet aggregation effects .

HY-N1861

3-O-Methylquercetin tetraacetate Quercetin 3-O-methyl ether peracetate	P2Y Receptor	Cardiovascular Disease Cancer
3-O-Methylquercetin tetraacetate is an antiplatelet agent. 3-O-Methylquercetin tetraacetate has potent antiplatelet effect on arachidonic acid, collagen-induced and PAF-induced platelet aggregation .

HY-N3668

Cyclomorusin Cyclomorusin A; Cyclomulberrochromene	Others	Cardiovascular Disease
Cyclomorusin (Cyclomorusin A; Cyclomulberrochromene) is a prenylflavonoid with antiplatelet activity. Cyclomorusin also inhibits markedly collagen-induced platelet aggregation .

HY-N3049

Piperlotine C	Others	Cardiovascular Disease
Piperlotine C is an alkaloid isolated from Piper lolot, with anti-platelet aggregation induced by arachidonic acid, and the IC₅₀ is 26.6 µg/mL .

HY-N12647

cis-Hinkiresinol	Others	Infection Inflammation/Immunology
cis-Hinkiresinol is a bioactive constituent of Rhizoma anemarrhenae. Rhizoma anemarrhenae is reprted to have anti-pathogenic microorganism, hypoglycemic effects, anti-inflammatory, antipyretic effects and anti-platelet aggregation .

HY-162375

AF299	Others	Cardiovascular Disease
AF299 can reduce collagen-related peptide-induced platelet Ca ²⁺ rises and collagen-induced platelet aggregation. AF299 can be used for research of antiplatelet research .

HY-U00367

(4E)-SUN9221	Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease Endocrinology
(4E)-SUN9221 is a potent antagonist of α1-adrenergic receptor and 5-HT2 receptor, with antihypertensive and anti-platelet aggregation activities.

HY-111447

VAS 3947	NADPH Oxidase Apoptosis	Cardiovascular Disease Cancer
VAS 3947, a specific NADPH oxidase (NOX) inhibitor, exerts a potent antiplatelet effect. VAS3947 induces apoptosis independently of anti-NOX activity, via UPR activation, mainly due to aggregation and misfolding of proteins .

HY-N12067

Columbianetin β-D-glucopyranoside	Others	Inflammation/Immunology
Columbianetin β-D-glucopyranoside can be isolated from Angelicae pubescentis radix and has antiplatelet aggregation, anti-inflammatory and analgesic activities. Columbianetin β-D-glucopyranoside exerts significant protective effects against glutamate-induced toxicity .

HY-N0120

(E/Z)-Polydatin (E/Z)-Piceid	Others	Inflammation/Immunology
(E/Z)-Polydatin ((E/Z)-Piceid) is a monocrystalline compound originally isolated from the root and rhizome of Polygonum cuspidatum. (E/Z)-Polydatin has anti-platelet aggregation, anti-oxidative action of low-density lipoprotein (LDL), cardioprotective activity, anti-inflammatory and immune-regulating functions .

HY-10119

Vorapaxar 5+ Cited Publications SCH 530348	Protease Activated Receptor (PAR)	Cardiovascular Disease
Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (K_i=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .

HY-10119A

Vorapaxar sulfate 5+ Cited Publications SCH 530348 sulfate	Protease Activated Receptor (PAR)	Cardiovascular Disease
Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (K_i=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .

HY-19638

Cangrelor AR-C69931MX
Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist .

HY-15284

Prasugrel PCR 4099	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284A

Prasugrel hydrochloride PCR 4099 hydrochloride	P2Y Receptor	Cardiovascular Disease
Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284B

Prasugrel (Maleic acid) PCR 4099 (Maleic acid)	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-108555

FR-171113	Protease Activated Receptor (PAR)	Cardiovascular Disease
FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC₅₀ of 0.29 μM. .

HY-128345

UDM-001651	Protease Activated Receptor (PAR)	Cardiovascular Disease
UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC₅₀=4 nM; K_d=1.4 nM). UDM-001651 shows antiplatelet potency (IC₅₀=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP) .

HY-78263

MNS NSC 170724; 5-(2-Nitrovinyl)benzodioxole	Src Syk	Cancer
MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC₅₀ values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS inhibits Src, Syk, and FAK with IC₅₀ of 27.3, 2.8, and 97.6 μM, respectively .

HY-17459S

Clopidogrel-d3 hydrogen sulfate (S)-(+)-Clopidogrel bisulfate-d₃; (S)-(+)-Clopidogrel-d₃ hydrogen sulfate	P2Y Receptor Cytochrome P450
Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

HY-17459R

Clopidogrel hydrogen sulfate (Standard) (S)-(+)-Clopidogrel bisulfate (Standard); (S)-(+)-Clopidogrel hydrogen sulfate (Standard)	Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an *antiplatelet* agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-P99560

Tadocizumab C4G1; YM-337	Integrin	Cardiovascular Disease
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .

HY-P1956

Human serum albumin 1 Publications Verification HSA	NF-κB NO Synthase	Cardiovascular Disease Inflammation/Immunology
Human serum albumin (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, NF-κB, and peroxynitrite (ONOO ⁻) in the vascular wall, contributing to the reduction of blood pressure .

HY-N2515

Ginsenoside Rk1 2 Publications Verification	NF-κB PI3K JAK Apoptosis	Inflammation/Immunology Cancer
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures . Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB . Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis . Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .

HY-149454

P2Y1/P2Y12 antagonist-1	P2Y Receptor	Cancer
P2Y1/P2Y12 antagonist-1 (compound 24w) is an orally available dual inhibitor of P2Y1 and P2Y12 with antiplatelet activity. P2Y1/P2Y12 antagonist-1 inhibits ADP-induced platelet aggregation in rabbit plasma with an IC₅₀ of 4.23 μM. P2Y1/P2Y12 antagonist-1 exhibits potent inhibitory effects in rat thrombosis model.

Human serum albumin 1 Publications Verification HSA	Native Proteins
Human serum albumin (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, NF-κB, and peroxynitrite (ONOO ⁻) in the vascular wall, contributing to the reduction of blood pressure .

Tadocizumab C4G1; YM-337	Integrin	Cardiovascular Disease
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2081

Skimmianine 1 Publications Verification	Alkaloids Classification of Application Fields Skimmia reevesiana Fort. Source classification Rutaceae Quinoline Alkaloids Plants Disease Research Fields Inflammation/Immunology	Others
Skimmianine is a furoquinoline alkaloid present mainly in the Rutaceae family, with antispastic, anti-inflammatory activities and antiplatelet aggregation effect. Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity .

HY-N7991

Rubiayannone A	Cardiovascular Disease Quinones Classification of Application Fields Anthraquinones Source classification Rubiaceae Phenols Polyphenols Rubia yunnanensis Diels Plants Disease Research Fields	Others
Rubiayannone A is an anthraquinone glycoside with an antiplatelet aggregation activity .

HY-N3048

Piperlotine D	Structural Classification Alkaloids Pyrrole Alkaloids Piper sarmentosum Roxb. Source classification Piperaceae Plants	Others
Piperlotine D is an antiplatelet aggregation agent. Piperlotine D can be extracted from Piper lolot with antiplatelet aggregation activity. Piperlotine D inhibits arachidonic acid-induced platelet aggregation with an IC₅₀ of 43.4 μg/mL .

HY-125123

Euchrestaflavanone A	Structural Classification Flavonoids Flavones Leguminosae Source classification Sophora alopecuroides L Plants	Others
Euchrestaflavanone A is a flavonoid found in the root bark of Cudrania tricuspidate. Euchrestaflavanone A inhibits platelet aggregation and has some antiplatelet and antithrombotic properties, making it a potential compound for thromboprophylaxis .

HY-N4228

6-Methoxydihydroavicine	Alkaloids Structural Classification Classification of Application Fields Source classification Quinoline Alkaloids Macleaya cordata (Willd.) R. Br. Plants Disease Research Fields Papaveraceae Cancer	Platelet-activating Factor Receptor (PAFR)
6-Methoxydihydroavicine is an alkaloid isolated from Zanthoxylum integrifoliolum. 6-Methoxydihydroavicine has *antiplatelet* activities and inhibits AA-, collagen- and PAF-induced platelet aggregation in vitro .

HY-N11920

Kadsurenin B	Structural Classification Source classification Lignans Piperaceae Phenylpropanoids Plants Piper kadsura (Choisy) Ohwi	Platelet-activating Factor Receptor (PAFR)
Kadsurenin B is a PAF (platelet-activating factor) antagonist with neuroprotective activity. Kadsurenin B has a wide range of pharmacological research potential, such as antibacterial, anti-inflammatory, neuroprotective, antioxidant, antiplatelet aggregation, cytotoxic, antiparasitic, etc .

HY-N0293

Paeoniflorin Maximum Cited Publications 16 Publications Verification Peoniflorin	Structural Classification Other Monoterpenes Paeonia lactiflora Pall. Terpenoids Source classification Plants Paeoniaceae	HSP
Paeoniflorin is a heat shock protein-inducing compound and commonly exists in the plants of Paeoniaceae family, with various biological activities, including anticancer activity, anti-inflammatory activity, enhancing cognition and attenuating learning impairment, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, and reducing blood viscosity .

HY-N3051

Piperlotine A	Cardiovascular Disease Alkaloids other families Pyrrole Alkaloids Classification of Application Fields Source classification Plants Disease Research Fields	Others
Piperlotine A is an alkaloid isolated from Piper lolot, with potent antiplatelet aggregation activity .

HY-N3047

Piperolactam C O-Methylpiperolactam B; Piperolactam B methyl ether	Structural Classification Alkaloids Piper taiwanense Lin & Lu Other Alkaloids Source classification Piperaceae Plants	Others
Piperolactam C (O-Methylpiperolactam B) is a natural alkaloid with anti-platelet aggregation effects .

HY-N1861

3-O-Methylquercetin tetraacetate Quercetin 3-O-methyl ether peracetate	Rhamnus nakaharai (Hayata) Hayata Structural Classification Flavonoids Flavones Source classification Plants Rhamnaceae	P2Y Receptor
3-O-Methylquercetin tetraacetate is an antiplatelet agent. 3-O-Methylquercetin tetraacetate has potent antiplatelet effect on arachidonic acid, collagen-induced and PAF-induced platelet aggregation .

HY-N3668

Cyclomorusin Cyclomorusin A; Cyclomulberrochromene	Flavonoids Source classification Plants Moraceae Other Flavonoids Morus alba Linn.	Others
Cyclomorusin (Cyclomorusin A; Cyclomulberrochromene) is a prenylflavonoid with antiplatelet activity. Cyclomorusin also inhibits markedly collagen-induced platelet aggregation .

HY-N3049

Piperlotine C	Cardiovascular Disease Alkaloids Pyrrole Alkaloids Classification of Application Fields Source classification Piperaceae Plants Disease Research Fields Piper nigrum Linn.	Others
Piperlotine C is an alkaloid isolated from Piper lolot, with anti-platelet aggregation induced by arachidonic acid, and the IC₅₀ is 26.6 µg/mL .

HY-N12647

cis-Hinkiresinol	Structural Classification Liliaceae Source classification Phenols Polyphenols Anemarrhena asphodeloides Bunge Plants	Others
cis-Hinkiresinol is a bioactive constituent of Rhizoma anemarrhenae. Rhizoma anemarrhenae is reprted to have anti-pathogenic microorganism, hypoglycemic effects, anti-inflammatory, antipyretic effects and anti-platelet aggregation .

HY-N12067

Columbianetin β-D-glucopyranoside	Structural Classification Source classification Plants Umbelliferae Seriphidium transiliense Saccharides Monosaccharides	Others
Columbianetin β-D-glucopyranoside can be isolated from Angelicae pubescentis radix and has antiplatelet aggregation, anti-inflammatory and analgesic activities. Columbianetin β-D-glucopyranoside exerts significant protective effects against glutamate-induced toxicity .

HY-N0120

(E/Z)-Polydatin (E/Z)-Piceid	Stilbenes Classification of Application Fields Polygonaceae Source classification Reynoutria japonica Houtt. Phenols Polyphenols Plants Disease Research Fields Inflammation/Immunology	Others
(E/Z)-Polydatin ((E/Z)-Piceid) is a monocrystalline compound originally isolated from the root and rhizome of Polygonum cuspidatum. (E/Z)-Polydatin has anti-platelet aggregation, anti-oxidative action of low-density lipoprotein (LDL), cardioprotective activity, anti-inflammatory and immune-regulating functions .

HY-N2515

Ginsenoside Rk1 2 Publications Verification	Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields Araliaceae	NF-κB PI3K JAK Apoptosis
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures . Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB . Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis . Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .

Cat. No.	Product Name	Chemical Structure

HY-17459S

Clopidogrel-d3 hydrogen sulfate

Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

antiplatelet aggregation

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products